Galectin Therapeutics Inc. (GALT) is a publicly traded Healthcare sector company. As of September 10, 2026, GALT trades at $4.01 with a market cap of $417.52M and a P/E ratio of -8.58. GALT moved +0.00% today. Year to date, GALT is -2.64%; over the trailing twelve months it is -18.18%. Its 52-week range spans $1.11 to $7.13. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces GALT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for GALT shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $4.01 |
| Market Cap | $417.52M |
| P/E Ratio | -8.58 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.13 |
| 52-Week Low | $1.11 |
| Volume | 25.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-30.84M |
| Gross Margin | 0.00% |
1 analysts cover GALT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.